This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Key Points
Kynam Capital sold 2,957,386 shares of Viridian Therapeutics in the fourth quarter; the estimated trade size was $81.11 million based on quarterly average pricing.
Meanwhile, the quarter-end Viridian position value fell by $49.79 million, reflecting both trading and price movements.
The quarter-end holding stood at 1,470,541 shares valued at $45.76 million.
- 10 stocks we like better than Viridian Therapeutics ›
Kynam Capital Management trimmed its stake in Viridian Therapeutics (NASDAQ:VRDN), selling 2,957,386 shares in the fourth quarter, an estimated $81.11 million transaction based on quarterly average pricing, according to a February 17, 2026, SEC filing.
What happened
According to a filing with the U.S. Securities and Exchange Commission dated February 17, 2026, Kynam Capital Management reduced its holding in Viridian Therapeutics by 2,957,386 shares during the fourth quarter. The estimated transaction value is $81.11 million, calculated using the average closing price for the quarter. The value of the Viridian stake at quarter-end declined by $49.79 million, a figure that includes both trading and market price effects.
What else to know
- The fund sold shares, bringing its Viridian stake to 2.92% of 13F reportable assets under management.
- Top five holdings after the filing:
- NASDAQ:COGT: $218.99 million (14.3% of AUM)
- NASDAQ:VERA: $173.85 million (11.3% of AUM)
- NASDAQ:SNDX: $169.15 million (11.0% of AUM)
- NASDAQ:CLDX: $161.42 million (10.5% of AUM)
- NASDAQ:PCVX: $134.84 million (8.8% of AUM)
- As of Friday, Viridian shares were priced at $26.98, up 76% over the past year and well outperforming the S&P 500’s roughly 15% gain in the same period.
Company overview
| Metric | Value |
|---|---|
| Price (as of Friday) | $26.98 |
| Market capitalization | $2.8 billion |
| Revenue (TTM) | $70.79 million |
| Net income (TTM) | ($342.6 million) |
Company snapshot
- Viridian Therapeutics develops monoclonal antibody therapies, with a current focus on treatments for thyroid eye disease (TED), including lead candidates VRDN-001, VRDN-002, and VRDN-003.
- The company’s business model is centered on research and development of novel biologics, advancing candidates through clinical trials to achieve regulatory approval and future commercialization.
- Viridian primarily targets healthcare providers and patients affected by serious diseases, with an emphasis on the biotechnology market.
Viridian Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of innovative antibody-based therapies for serious diseases. With a pipeline led by candidates targeting thyroid eye disease, the company leverages advanced monoclonal antibody technology to address unmet medical needs. Viridian’s strategy is rooted in scientific expertise and a focus on high-value specialty markets, positioning it to compete in the evolving biotechnology sector.
What this transaction means for investors
When a biotech position balloons this quickly, trimming becomes less about conviction and more about control. Viridian had turned into one of the fund’s core bets, with nearly $100 million worth of holdings. But after a staggering stock run over the past year, this trim seems like an effort to right-size risk without walking away from the story entirely.
Viridian heads into a pivotal stretch with a June 30 PDUFA date for veligrotug, plus multiple Phase 3 readouts for its follow-on candidate VRDN-003 expected this year. At the same time, it is spending heavily to get there, with research and development costs climbing to nearly $339 million and a full-year net loss of about $343 million. That said, the balance sheet helps offset that risk, with roughly $875 million in cash at year-end. For long-term investors, this remains a high-conviction pipeline story, but one now sized more appropriately after a major run. Upcoming data will play a pivotal role in how the performance holds up.
Should you buy stock in Viridian Therapeutics right now?
Before you buy stock in Viridian Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viridian Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $495,179!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,058,743!*
Now, it’s worth noting Stock Advisor’s total average return is 898% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 21, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.